Sillajen’s co-development agreement of renal cancer treatment with U.S. RegeneronPharmaceuticals
Sillajen(CEO Eun-Sang Moon) announced in a joint statement on the 8th that it signed a co-research agreement of renal cell carcinoma(renal cancer) treatment development with U.S. ‘RegeneronPharmaceuticals.’
Under the agreement, the two companies are planning to conduct a Phase 1b clinical trial ...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.